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Abstract
 Background aims—The PR1 peptide, derived from the leukemia-associated antigens 
proteinase 3 and neutrophil elastase, is overexpressed on HLA-A2 in acute myeloid leukemia 
(AML). We developed a T cell receptor (TCR)-like monoclonal antibody (8F4) that binds the PR1/
HLA-A2 complex on the surface of AML cells efficiently killing them in vitro and eliminating 
them in preclinical models. Humanized 8F4 (h8F4) with high affinity for the PR1/HLA-A2 
epitope was used to construct an h8F4- chimeric antigen receptor (CAR) that was transduced into 
T-cells to mediate anti-leukemia activity.
 Methods—Human T cells were transduced to express the PR1/HLA-A2-specific CAR (h8F4-
CAR-T cells) containing the scFv of h8F4 fused to the intracellular signaling endodomain of CD3 
zeta chain through the transmembrane and intracellular costimulatory domain of CD28.
 Results—Adult human normal peripheral blood (PB) T cells were efficiently transduced with 
the h8F4-CAR construct and predominantly displayed an effector memory phenotype with a minor 
population (12%) of central memory cells in vitro. Umbilical cord blood (UCB) T cells could also 
be efficiently transduced with the h8F4-CAR. The PB and UCB-derived h8F4-CAR-T cells 
specifically recognized the PR1/HLA-A2 complex and were capable of killing leukemia cell lines 
and primary AML blasts in an HLA-A2-dependent manner.
 Conclusions—Human adult PB and UCB-derived T cells expressing a CAR derived from the 
TCR-like 8F4 antibody rapidly and efficiently kill AML in vitro. Our data could lead to a new 
Address correspondence to: Jeffrey J. Molldrem, Section of Transplantation Immunology, Department of Stem Cell Transplantation 
and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Unit 900, 1515 Holcombe Boulevard, Houston, TX 77030, 
Tel. 713-563-3334; Fax. 713-563-3364; jmolldre@mdanderson.org.
†These authors contributed equally to this manuscript.
Authorship statement: H.R.G., S.LJ., E.T., X.D., H.H., and L.St J. performed experiments. H.R.G., S.LJ., E.T. and H.H. analyzed data. 
A.S., G.D. and B.S. provided reagents. H.R.G., S.L.J.,, E.T., G.A., K.R., and E.J.S. wrote the paper. Q.M. and J.J.M. designed the 
research and wrote the paper. We have no conflict of interests.
HHS Public Access
Author manuscript
Cytotherapy. Author manuscript; available in PMC 2017 August 01.
Published in final edited form as:













treatment paradigm for AML in which targeting leukemia stem cells could transfer long-term 
immunity to protect against relapse.
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 Introduction
Adoptive cellular therapy employs high-affinity B and/or T-cell antigen receptors to 
eliminate malignant cells and is a promising therapy for hematologic malignancies. This 
strategy has been most effective in the treatment of adult and pediatric acute lymphoblastic 
leukemia (ALL), where CAR-expressing T cells redirected against the CD19 antigen have 
achieved high clinical response rates and durable remissions in patients with relapsed, 
refractory disease [1, 2]. CAR-T cells are T lymphocytes that are genetically engineered to 
express the single chain variable fragment (scFv) derived from a B-cell immunoglobulin (Ig) 
receptor, and the resulting chimeric cell combines the advantages of a highly specific B-cell 
Ig receptor with the potent cytotoxicity of T-cells. There is an urgent clinical need to 
translate this biotechnology into therapy for AML, a disease for which the standard 
treatment strategy has remained unchanged for 30 years despite only a minority of patients 
achieving durable remissions [3].
We have led the investigation of the leukemia-associated antigen PR1, a human leukocyte 
antigen-A2*0201 (HLA-A2)-restricted nonameric peptide derived from the parent proteins 
neutrophil elastase and proteinase 3. These serine proteases are present in the primary 
azurophilic granules of neutrophils but are overexpressed and mislocalized in myeloid 
leukemia blasts [4, 5]. Previously, we showed that PR1-specific cytotoxic T-cells can be 
identified in the peripheral blood of myeloid leukemia patients, mediate cytotoxicity against 
leukemic blasts in vitro, reduce the leukemic burden in an AML xenograft model, and are 
associated with the graft-versus-leukemia effect after allogeneic stem cell transplantation 
(allo-SCT), and [6–9]. Recently, we developed an anti-PR1/HLA-A2 TCR-like antibody, 
8F4, that mediates complement-dependent cytolysis of AML blasts and leukemia stem cells 
in vitro and in vivo [10, 11]. TCR-like antibodies are a unique and novel class of biologics 
that challenge the paradigm that monoclonal antibodies (mAbs) can recognize only 
extracellular proteins and, instead, vastly expand the number of potential mAb-binding 
tumor antigens to include intracellular peptides bound to a surface MHC molecule. TCR-like 
antibodies are attractive because they can bind targets with affinities that are logs higher than 
the TCR [12, 13]. The PR1-targeting humanized 8F4, h8F4, will enter an early phase clinical 
trial for myeloid leukemia patients next year [14].
Herein, we report the incorporation of the h8F4 scFv into a 2nd generation retroviral TCR-
like CAR construct and demonstrate efficient transduction of the CAR vector into human 
healthy donor (HD) peripheral blood mononuclear cells (PBMCs). We show consistent, high 
expression of the h8F4-CAR on the surface of both CD4+ and CD8+ T-cells. We also show 
specific binding of the h8F4-CAR to the HLA-A2/PR1 antigen and demonstrate preferential 
cytotoxicity of h8F4-CAR-T cells against human AML cell lines and primary AML blasts in 
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vitro. In addition, we show efficient transduction and functional cytotoxicity of h8F4-CAR-
T cells generated from umbilical cord blood,; a versatile source of cells for adoptive therapy 
that is more permissive for HLA-mismatching in the allo-SCT setting and that may possess 
enhanced antitumor efficacy [15, 16].
 Materials and Methods
 Reagents
PBMCs were isolated from buffy coat preparations derived from whole blood of healthy 
volunteer donors (Gulf Coast Regional Blood Center, Houston, TX). HLA-A2 positive fresh 
UCB units were obtained from the MD Anderson Cord Blood Bank. PBMC and UCB were 
separated by gradient density centrifugation using Histopaque 1077 (Sigma-Aldrich). HLA-
A2*0201 (HLA-A2+) samples were identified by staining blood samples with anti-HLA-A2 
antibody (clone BB7.2; BD Pharmingen). AML samples were collected from patients treated 
at the University of Texas MD Anderson Cancer Center under protocols approved by the 
Institutional Review Board. HLA status of patients was determined by the MD Anderson 
HLA Typing Laboratory. T2, K562, and U937 cell lines were obtained from American Type 
Culture Collection. HLA-A2*0201 transduction of cell lines was performed as previously 
described using lentiviral vectors [17].
 Generation of the HLA-A2/PR1-specific CAR construct
The humanized antibody targeting the PR1/HLA-A2 combined epitope produced by the 8F4 
hybridoma was cloned as a single chain (scFv) [18]. The genes coding the VH and VL 
chains of the monoclonal antibody were cloned by RT-PCR using murine variable domain-
specific primers modified to generate SfiI restriction sites at the 5′ end of the amplified VL 
and 3′ end of the amplified VH.26. Combinatorial scFv genes were generated by splicing-
by-overlap PCR and then ligated into SfiI sites of the replicative form of fUSE5 vector 
phage DNA. To generate the h8F4-CAR, the scFv sequence was cloned in frame with the 
human IgG1-CH2CH3 domain, CD28 costimulatory domain, and with the ζ chain of the 
TCR/CD3 complex in the SFG retroviral backbone [19, 20].
 Generation and transduction of activated T cells
To generate CAR-T cells, healthy donor PBMCs or UCB were activated on day 0 using 1 
μg/ml plate-bound anti-CD3 and anti-CD28 antibodies (clones HIT3a and CD28.2, 
respectively; BioLegend) in non-tissue culture treated 24-well plates (Falcon). On day 1, 100 
IU/ml of rhIL-2 (R&D Systems) was added to the PBMCs and a second 24-well plate was 
coated with 10 μg/ml recombinant fibronectin fragment (Takara) and left at 4°C overnight. 
The following day, h8F4-CAR retroviral supernatant was added to the fibronectin plate and 
the plate was centrifuged at 2000×g for 90 minutes at room temperature. The supernatant 
was then aspirated and 1–2 million activated T cells were added per well. The T cells were 
subsequently expanded with rhIL-2 (50 IU/ml) and fresh T-cell medium every 3 days. T-cell 
medium consisted of 50% RPMI 1640 (HyClone) and 50% Click’s (Irvine Scientific) 
supplemented with 10% FBS, 100U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-
glutamine. Transduction efficiency was routinely assessed on day 6.
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 Phenotypic analysis of h8F4-CAR-T cells
Aliquots of transduced T cells were analyzed by 7-color flow cytometry using a panel of 
surface molecule specific antibodies, peptide tetramer, and dextramer: CD3 (clone SK7, 
Biolegend), CD4 (clone RPA-T4; Biolegend), CD8 (clone 3B5; Biolegend), anti-IgG 
(polyclonal Goat anti-human; Jackson ImmunoResearch), CD45RA (clone MEM-56; 
Thermo Fisher), and CCR7 (clone 3D12; BD Biosciences); HLA-A*0201 PR1 tetramer 
(Baylor tetramer core facility), HLA-A*0201 CMV pp65 dextramer and HLA-A*0201 PR1 
dextramer (Immudex, Denmark).
 Cytotoxicity assay
Freshly transduced h8F4-CAR-T cells were tested for specific cytotoxicity against target 
cells. Target cells were stained with 5 μg/ml of Calcein AM (Thermo Fisher) for 15 minutes 
at 37°C, washed, and resuspended at 2×105/ml in culture media. Two-thousand target cells 
in 10 μl were incubated with effector cells (CAR-transduced or control cytotoxic T-
lymphocytes (CTL)) at varying E:T ratios with 5 μl of 0.4% Trypan Blue added into each 
well of a Terasaki plate to quench the reaction [18, 21]. The BioTek FLx800 Microplate 
fluorescence reader was used to read the plate. The fluorescence was maximal in wells with 
targets alone and minimal in those with media alone or 100% dead cells; % specific lysis = 
(1−(mean value of test)/(mean value of target alone)) × 100.
 Results
 Expression of the h8F4-CAR on primary human T cells
The TCR-like mAb, h8F4, was used to construct an h8F4-CAR that, when transduced into 
polyclonal T cells, could redirect them to mediate graft-versus-leukemia (GVL) activity. The 
single chain variable fragments (scFv) of h8F4, including the variable region of light chain 2 
(VL2) and variable region of heavy chain (VH), were cloned in frame with the human IgG1-
CH2CH3 domain and the ζ chain of the TCR/CD3 complex in the SFG retroviral backbone 
[19, 20] (Figure 1). The CD28 domain within the construct was included as described [22]. 
Retroviral supernatant packaged in 293T cells was used to transduce human primary T cells. 
The transduction efficiency was measured using an anti-IgG antibody, the F(ab)2 fragment 
against IgG (heavy and light chains), that recognizes the spacer region of the CAR. On day 6 
post-transduction, cells were collected and stained with antibodies against the CD3 and the 
CAR spacer region. As shown in Figure 2A, ~95% of T cells expressed h8F4-CAR on their 
surface (CD3+/Anti-IgG+) compared to the background level (0.025%) on non-transduced 
control cells that underwent an identical activation process. Transduced T cells were 
maintained in culture with rhIL-2 for over 3 weeks. The transduction efficiency of h8F4-
CAR remained similar on day 15 and 21 post-transduction, 95.6% and 97.1% respectively 
(Figure 2B). Moreover, the consistently high expression of h8F4-CAR (> 80%) was 
achieved in 14 out of 19 different samples. Thus, primary human adult T cells are efficiently 
transduced with h8F4-CAR and expression remains stably high over time in vitro.
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 h8F4-CAR-T cells specifically recognize the PR1/HLA-A2 antigen
To determine whether the antigen receptor maintained recognition of the PR1/HLA-A2 
ligand, h8F4-CAR-T cells and non-transduced T cells were stained with CD3 Ab and either 
PR1/HLA-A2 tetramer (Figure 3A, left panels) or PR1/HLA-A2 dextramer (Figure 3A, right 
panels). The h8F4-CAR-T-cells showed high avidity for the PR1/HLA-A2 antigen at levels 
comparable to that seen with the anti-IgG antibody (Figure 2A). When using equivalent 
concentrations of PR1/HLA-A2 dextramer and CMV pp65/HLA-A2 dextramer in a 
competition assay, h8F4-CAR transduced T cells demonstrated preferential binding to PR1 
and not irrelevant pp65, regardless of whether cells were first incubated with PR1 dextramer 
(Figure 3B–a) or CMVpp65 dextramer (Figure 3B–b). These data indicate that the h8F4 
TCR-like antibody maintains specificity for the HLA-A2/PR1 ligand when expressed on the 
surface of T-cells as chimeric antigen receptors. Both CD4 and CD8 T cells were transduced 
with h8F4-CAR equally well (Figure 3C); however, the CD4:CD8 ratio of the CAR-
transduced T-cells varied by donor. Among adult PB donors, the percentage of CD4+ CAR 
cells was 50–60% on average on day 6 post-transduction. The percentage of CD4+ CAR-T 
cells was higher in UCB-derived cells and was 70% on average, which was expected given 
the higher average frequency of CD4+ T cells in fresh cord units [23]. As shown in Figure 
3D, h8F4-CAR transduced T cells were predominantly effector memory cells (CCR7−/
CD45RA−) with 12% displaying a central memory phenotype (CCR7+/CD45RA−).
 Human T cells modified with the high affinity h8F4-CAR mediate anti-leukemic activity
Since h8F4 has higher affinity than the PR1-TCR for the PR1/HLA-A2 ligand [14], we 
investigated whether h8F4-CAR transduced T cells were capable of killing PR1/HLA-A2 
target cells in vitro. As shown in Figure 4A, h8F4-CAR-T cells lysed PR1-pulsed but not 
control peptide CMV pp65 peptide-pulsed T2 cells, demonstrating that h8F4-CAR-T cells 
were capable of killing T2 targets in a peptide-dependent manner. Furthermore, h8F4-CAR-
T cells lysed the HLA-A2 transduced, PR1-expressing leukemia cell lines U937 (U937-A2) 
and K562 (K562-A2) but not their wild type counterparts, which express PR1 but not HLA-
A2 (Figure 4B). Specific killing of primary patient HLA-A2+ AML blasts by h8F4-CAR-T 
cells was also demonstrated (Figure 5C), indicating that h8F4-CAR-T cells were capable of 
killing leukemia cell lines and primary AML blasts in an HLA-A2-dependent manner.
 h8F4-CAR transduced UCB T cells lyse human leukemia target cells
Human UCB T cells were transduced with the h8F4-CAR, and as shown in Figure 5A (left), 
high expression of h8F4-CAR on UCB T cells was confirmed on day 6 post-transduction 
(98.3%). Among five different individual UCB samples, four demonstrated high expression 
of h8F4-CAR with over 85% T-cell transduction (Figure 5A, right). Both CD4 and CD8 
cord blood T cells were transduced equally well with h8F4-CAR virus (Figure 5B). As 
shown in Figure 5C, h8F4-CAR transduced UCB T cells were predominantly effector 
memory cells (CCR7−/CD45RA−). To measure the specific cytotoxic activity of h8F4-CAR 
UCB T cells, U937 leukemia cells (both HLA-A2-transduced and wild type) and primary 
human patient AML blasts were used as targets in a cytotoxicity assay. As shown in Figure 
5D, UCB-derived h8F4-CAR-T cells were capable of killing the U937-A2 leukemia cell line 
and primary AML blasts in an HLA-A2-dependent manner in vitro.
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We recently developed a T cell receptor-like murine IgG2a monoclonal antibody, m8F4, 
which binds to PR1/HLA-A2+ AML, mediates lysis of AML in vitro, and depletes AML in 
vivo [10, 11]. Mouse 8F4 was humanized - human IgG1 8F4 (h8F4) - and maintains 
specificity for PR1/HLA-A2 and activity against AML [14]. The h8F4 mAb has high affinity 
(Kd = 6.5 nM) for the PR1/HLA-A2 conformational epitope [14]. Thus, it is an ideal TCR-
like mAb for constructing an 8F4-CAR to transduce T-cells and redirect them to mediate 
GVL activity against myeloid malignancies. Potential advantages of CAR-modified T cells 
over monoclonal antibodies include greater cytotoxic potency, active trafficking, passage 
through the blood-brain barrier, fewer required doses, the potential for long-lived memory 
and protection against relapse, and increased sensitivity to low antigen density [24, 25]. 
Disadvantages include the greater potential for on-target, off-tissue toxicity and less control 
over the dose and schedule as CARs have the potential for immense proliferation in vivo.
To test whether an h8F4-CAR antigen receptor expressed in T-cells mediated anti-leukemia 
activity in vitro, we generated human adult PB and UCB-derived T cells modified to express 
PR1/HLA-A2 complex-specific CAR (h8F4-CAR-T). We demonstrated the specificity of 
h8F4-CAR-T cells, which preferentially bound PR1 dextramer. TCR-like antibodies, such as 
h8F4, are unique in their binding properties and must have affinity for both the target HLA 
molecule and the peptide-MHC complex to ensure recognition. We anticipated that h8F4-
CAR-T cells would demonstrate low-avidity binding to irrelevant dextramer due to the 
clustering of CAR receptors on the surface and the inherent HLA-A2 binding requirement as 
shown in Figure 3B(b). Encouragingly, however, the h8F4-CAR-T cells preferentially bound 
the relevant PR1 epitope. CAR-modified T cells are potent and do have the potential for on-
target, off-tissue toxicity in cases where the antigenic target is co-expressed on normal cells, 
such as with leukemia-associated antigens. Though we have shown that PR1-targeting 
strategies, including PR1-specific CTL and the 8F4 mAb, preferentially inhibit leukemia 
progenitor cells over normal hematopoietic progenitors [5, 10, 11, 21], the potential for 
h8F4-CAR-T cell toxicity exists. We recognize that clinical application of the h8F4-CAR-T 
cells may require a system where the construct is either transiently expressed [26, 27] or 
where the CAR is expressed in tandem with a suicide gene “switch” [19].
In this report, we demonstrated functional specificity of the h8F4-CAR-T cells, which killed 
PR1-pulsed T2 cells but not control-peptide-pulsed T2 cells and lysed HLA-A2 transduced 
U937 and K562 leukemia cell lines as well as HLA-A2+ primary AML blasts but not HLA-
A2-negative AML or HLA-A2 negative leukemia cell lines. We conclude that T cells 
expressing a CAR derived from the TCR-like 8F4 antibody rapidly and efficiently kill AML 
in vitro and that this novel adoptive T cell approach merits further investigation.
Considerable research is focused on identifying and targeting extracellular proteins on the 
surface of AML blasts using CAR-T cells, and strong preclinical evidence exists for CAR-T 
cells that target the antigens CD123 and CD33 [28–30]. However, these antigens are 
coexpressed on the surface of myeloid progenitor cells and additional safeguards will need 
to be implemented to prevent on-target, off-tissue toxicity, long-term myelosuppression, and 
consequent infections [30]. Additionally, a predictable challenge to the success of targeting 
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specific leukemia antigens is clonal evolution and intratumoral heterogeneity, from which 
immune escape variants can emerge to comprise relapsed disease [31, 32]. One solution is to 
target multiple leukemia antigens simultaneously; however, the limited number of effective 
antigens currently hinders this approach. We identified 8F4 as the first TCR-like mAb 
against a leukemia antigen [10]. The successful development and testing of the h8F4-CAR 
shown here supports the promise of developing a novel T-cell therapy directed against an 
endogenous self-antigen that is differentially expressed on the surface of leukemia stem 
cells.
We also demonstrated that T cells derived from UCB could be efficiently transduced with 
the h8F4-CAR and were capable of killing leukemia cells in a PR1/HLA-A2-dependent 
manner. UCB lymphocytes are mostly naive T-cells and may be an ideal source for 
generating h8F4-CAR T cells [15, 16]. Since the first UCB transplant (CBT) was performed 
in 1988 by Gluckman et al. [33], more than 40,000 patients have received CBT for 
malignant and non-malignant diseases [34–40]. Importantly, UCB has improved the 
likelihood of finding a SCT donor for minority populations, who are under-represented in 
donor registries [41]. Of note, the HLA-A*02:01 allele is common among US African 
Americans (34–40% of individuals) and US Hispanic individuals (19–23%) in addition to 
being present at high rates in Caucasians (47% of individuals)[42–44]. To improve the 
outcome of CBT for patients with AML, the most common disease treated with CBT, graft 
engineering of donor T cells as demonstrated herein using UCB-derived h8F4-CAR-T cells 
could increase graft-versus-leukemia (GVL) without increasing graft-versus-host disease 
(GVHD). In support of this strategy, allogeneic CAR-T cells have already been used in at 
least 4 different clinical trials without any reports of acute GVHD [1, 2, 45, 46], and we 
anticipate UCB derived CAR-T cells will carry less risk of GVHD in this setting [47].
In summary, we have successfully developed a CAR-T cell based on the construct of a TCR-
like monoclonal antibody that targets an intracellular leukemia-associated antigen. We 
showed that this approach is feasible using peripheral blood as well as UCB T cells. This 
method could improve upon the existing cellular approaches to the therapy of leukemia and 
other malignancies.
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Figure 1. Humanized 8F4-CAR (h8F4) construct
Schematic plasmid map of humanized 8F4 antibody single chain variable fragments (scFv) 
containing the PR1/HLA-A2 chimeric antigen receptor (Hu8F4-ScFv-CAR). SP - signal 
peptide, VL2 variable region of light chain 2 of h8F4, VH variable region of heavy chain of 
h8F4, L - linker peptide GlyGlyGlyGlySer, CH2CH3 constant region 2 and 3 of human 
IgG1, CD28 CD28 signaling domain, zeta CD3 zeta chain.
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Figure 2. Human adult T cells are efficiently transduced with the h8F4 construct and expression 
remains stably high over time in vitro
Peripheral blood T cells were transduced with the h8F4-CAR retrovirus. Transduction 
efficiency was determined by flow cytometry using an anti-human IgG (heavy and light 
chain) antibody against the CAR spacer CH2CH3 region and anti-CD3. Non-transduced 
PBMCs were used as negative control. Representative flow cytometry plots of T cells 
expressing h8F4-CAR on day 6 (A), day 15, and day 21 (B) post-transduction. (C) Summary 
of the transduction efficiency from 19 individual experiments on day 6 represented by the 
percentage of anti-IgG+ T cells. Horizontal bars indicate mean values with SEM.
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Figure 3. h8F4-CAR-T cells specifically recognize the PR1/HLA-A2 antigen
(A) Representative flow cytometry plots demonstrating non-transduced activated control T 
cells (top) and h8F4-CAR transduced T cells (bottom) stained with either PR1-HLA*02:01 
tetramer (left panel) or PR1-HLA*02:01 dextramer (right panel). (B) h8F4-CAR-T cells 
preferentially bind PR1 dextramer. A dextramer competition assay was performed using 
equivalent concentrations of PR1-HLA*02:01 dextramer and irrelevant CMVpp65-
HLA*02:01 dextramer. h8F4-CAR-T cells were first incubated with PR1 dextramer for 3 
minutes before adding an equivalent concentration of CMVpp65 dextramer (a) or in the 
reverse sequence (b). Results for both dextramer channels are shown after gating on viable, 
single lymphocytes. (C) Both CD4 and CD8 T cells were transduced equally well with 
h8F4-CAR virus. Transduction efficiency was analyzed separately for CD4 and CD8 cells 
by flow cytometry on day 13 post-transduction using anti-human IgG antibody against the 
CAR spacer CH2CH3 region and anti-CD3. (D) Phenotype of transduced h8F4-CAR-T 
cells. Phenotype was determined using CCR7 and CD45RA cell surface markers. Left panel: 
representative plots of PBMCs prior to activation, non-transduced activated control cells, 
and h8F4-transduced CAR-T cells. Right panel: summary of effector memory (EM) 
(CCR7−/CD45RA−), central memory (CM) (CCR7+/CD45RA−) and terminally 
differentiated (TD) effector (CCR7−/CD45RA+) subsets of h8F4-CART cells in 3 different 
experiments.
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Figure 4. h8F4-CAR-T cells demonstrate specific cytotoxicity
(A) T2 target cells were loaded with PR1 peptide or control CMV pp65 peptide and 
incubated with h8F4-CAR-T cells at the indicated E:T ratios in a 4-hr cytotoxicity assay. (B) 
HLA-A2 transduced K562 (left panel) and U937 (right panel) leukemia cell lines and their 
wild type, HLA-A2 negative counterparts were incubated with h8F4-CAR-T cells at the 
indicated E:T ratios in a 4-hr cytotoxicity assay. (C) Primary human A2+ and A2− AML 
blasts were incubated with h8F4-CAR-T cells or NT cells at the indicated E:T ratios in a 4-
hr cytotoxicity assay. Data are presented as mean percent specific killing of target cells ± SD 
with experiments done in triplicate.
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Figure 5. Human cord blood T cells are efficiently transduced with the h8F4-CAR and 
demonstrate specific cytotoxicity
UCB-derived T cells were transduced with the h8F4-CAR virus. (A) Expression of h8F4-
CAR on cord blood T cells. Left: representative flow cytometry plot of cord blood T cells 
expressing h8F4-CAR on day 6 post-transduction. Right: summary of the transduction 
efficiency from 5 individual experiments. Horizontal bars indicate mean values with SEM. 
(B) Both CD4 and CD8 cord blood T cells were transduced equally well with the h8F4-CAR 
virus. Transduction efficiency was analyzed separately for CD4 and CD8 cells on day 6 
post-transduction using the anti-spacer antibody. (C) Phenotype of UCB-derived h8F4-CAR-
T cells was assessed using CCR7 and CD45RA cell surface markers. (D) Specific cytotoxic 
activity of h8F4-CAR cord blood T cells. Left: HLA-A2+ and wild type U937 cells were 
incubated with h8F4-CAR cord blood T cells in a cytotoxicity assay. Right: Primary HLA-
A2+ and HLA-A2− AML blasts were incubated with h8F4-CAR cord blood T cells in a 
cytotoxicity assay at the indicated E:T ratios in a 4-hr cytotoxicity assay. Data are presented 
as mean percent specific killing of target cells ± SD with experiments done in triplicate.
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